Gabapentin
Product Images NDC 64725-0138

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 64725-0138). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tya Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (64725 0138)

This is a description of a medication called Gabapentin, in the form of 300mg capsules. The medication comes in a bottle package containing 30 capsules. The manufacturer of the medication is Sun Pharmaceuticals, and it was packaged by T.Y.A. Pharmaceuticals located in Tallahassee, Florida. The bottle has a lot number of X0 and an expiration date of XX-XX-XX. The medication comes with an insert detailing the appropriate dosage, as it is not mentioned here.*

FDA Label Image

Gabapentin-fig01 (Gabapentin Fig01)

The text describes a graph showing weekly pain scores for a study with a dose titration period and a fixed dose period, comparing a placebo to a 3600 mg/day dose of Gabapentin. The graph displays a statistical significance level of p<0.01.*

FDA Label Image

Gabapentin-fig02 (Gabapentin Fig02)

The text describes a study on the effectiveness of Gabapentin in reducing pain. The study involved a 3-week dose titration period followed by a 4-week fixed dose period where patients were given either a placebo or Gabapentin in doses of 1800mg or 2400mg per day. The results of the study are shown in Figure 2 which displays weekly mean pain scores. It appears that Gabapentin, particularly in a dose of 2400mg per day, reduced pain significantly compared to the placebo group.*

FDA Label Image

Gabapentin-fig03 (Gabapentin Fig03)

The text describes the results of controlled postherpetic neuralgia (PHN) studies evaluating the percentage of patients with >50% reduction in pain score (i.e., responders) at endpoint for placebo (PBO) and gabapentin (GBP) treatment groups. The results are presented in Figure 3, with data from two separate studies, Study 1 and Study 2, shown for the GBP treatment group. The significance levels of the differences between the treatment groups are indicated with asterisks, with ***p<0.001 indicating a highly significant difference and **p<0.01 indicating a significant difference.*

FDA Label Image

Gabapentin-fig04 (Gabapentin Fig04)

This appears to be a description of a figure, possibly related to a study on Gabapentin as an adjunctive therapy for patients over 12 years of age with partial seizures. The figure shows the responder rates expressed as a difference from placebo by dose and study. The x-axis has values of 600, 900, 1200, and 1800 for daily dose in mg. The text does not provide any additional information about the study or its results.*

FDA Label Image

Gabapentin-structure (Gabapentin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.